CD8A and breast cancer: One study explored the combined effect of priming with Toll-like receptor agonist CpG and anti-PD-1 treatment one week prior to T-FUS application, which resulted in reduced macrophages and MDSCs, augmented IFN-γ-producing CD8+ T cells, and increased the proportion of M1 macrophages in BC-bearing mice (26, 42).